Real-World Use of Dalbavancin in Diabetic Foot Osteomyelitis: PEDDAL Study
Real-World-Anwendung von Dalbavancin bei diabetischer Fußosteomyelitis: PEDDAL-Studie
Journal of Clinical Medicine · 23.09.2025 · 14 (19) · 6705
DOI: 10.3390/jcm14196705 ↗Auf einen Blick
Bei 136 Patient:innen mit diabetischer Fußosteomyelitis zeigte Dalbavancin eine Heilungsrate von 80,9 %. Unerwünschte Ereignisse traten bei 5 % auf.
Fragestellung
Wie wirksam und sicher ist Dalbavancin in der Behandlung tiefer diabetischer Fußinfektionen mit Osteomyelitis im Versorgungsalltag?
Methode
Retrospektive, beobachtende multizentrische Studie in 9 spanischen und 1 irischen Krankenhaus.
Ergebnisse
136 Patient:innen; mittleres Alter 69 ± 12 Jahre; 80,9 % Heilung (95 %-KI 73,5–86,6 %) nach median 2 Dosen. Unerwünschte Ereignisse bei 5 %; CKD als Risikofaktor für Therapieversagen.
Schlussfolgerung der Autor:innen
Dalbavancin ist laut den Autor:innen wirksam und sicher zur Behandlung der diabetischen Fußosteomyelitis, auch bei komplexen Patient:innen und resistenten Mikroorganismen.
Kernaussagen
- Heilungsrate: 80,9 % (95 %-KI 73,5–86,6 %)
- Unerwünschte Ereignisse bei 5 % der Patient:innen
- Chronische Nierenkrankheit war Risikofaktor für Therapieversagen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.09.2025. Verfasst von Leonor Moreno Núñez und 15 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Hospital Universitario Fundación Alcorcón, Universidad Rey Juan Carlos, 28922 Madrid, Spain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Angelini.
Themen: Diabetisches Fußsyndrom
Abstract (Originalsprache)
Background
Data on antibiotic treatment for diabetic foot osteomyelitis are limited. This study aims to describe the real-world effectiveness and safety of dalbavancin in treating deep diabetic foot infections.
Methods
A retrospective, observational, multicenter study was conducted in nine Spanish hospitals and one Irish hospital. Patients with diabetic foot osteomyelitis treated with dalbavancin were included. Data on demographics, clinical characteristics, microbiology, antibiotic regimens, adverse events, and clinical outcomes were analyzed.
Results
Among 136 patients, 76% were male, with a mean age of 69 ± 12 years. Renal insufficiency was observed in 32%, and 6% required renal replacement therapy. Based on the McCabe scale, 70% of patients had a rapidly or ultimately fatal disease. Polypharmacy was noted in 83%, and 60% of infections were moderate. Dalbavancin was primarily used as second-line therapy (92%). The cure rate was 80.9% (95% CI: 73.5–86.6%), achieved after a median of two doses. Patients receiving dalbavancin as first-line therapy had a cure rate of 86%, comparable to 80% in second-line therapy, with no significant differences. Surgical interventions were required in 72% of cases, with minor amputations performed in 40% of patients. Polymicrobial infections were common (55%), and methicillin-resistant Staphylococcus aureus was identified in 26% of cases. Adverse events occurred in 5% of patients. Chronic kidney disease was the sole independent risk factor for therapeutic failure (IRR 0.80, 95% CI: 0.64–1.00, p = 0.045).
Conclusions
Dalbavancin is effective and safe for treating diabetic foot osteomyelitis, including in complex patients with resistant microorganisms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Infectious Diseases Department, Hospital Universitario Fundación Alcorcón, Universidad Rey Juan Carlos, 28922 Madrid, Spain.
- Microbiology Department, Sligo University Hospital, F91H684 Sligo, Ireland.
- Infectious Disease Department, Cruces University Hospital, Biobizkaia Research Institute, 48903 Baracaldo, Spain.
- Infectious Diseases Department, Hospital Clinic-IDIBAPS, Universitat de Barcelona, 08036 Barcelona, Spain.
- Infectious Disease Department, Hospital Ramón y Cajal (Madrid), IRYCIS (Instituto Ramón y Cajal de Investigación Sanitaria), CIBERINFEC (Centro de Investigación Biomédica en Red Enfermedades Infecciosas), 28034 Madrid,…
- Infectious Disease Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, 08035 Barcelona, Spain.
ORCID-Profile: Elena Bereciartua, Laura Morata, Rosa Escudero-Sánchez, Julia Sellares Nadal, Joan Gómez-Junyent, Ana María Arnáiz García, María Dolores Del Toro López, Marina Torío-Salvador, Miguel Ángel Verdejo, María Velasco Arribas
Förderung
- Angelini
Zitieren
APA
Núñez, L. M., Benito, A. R., Bereciartua, E., Morata, L., Escudero-Sánchez, R., Nadal, J. S., Gómez-Junyent, J., Botrán, A. S., García, A. M. A., Del Toro López, M. D., Ruiz-Cabrera, D., Andrino, J. M. R., Alidrous, F., Torío-Salvador, M., Verdejo, M. Á., & Velasco Arribas, M. (2025). Real-World Use of Dalbavancin in Diabetic Foot Osteomyelitis: PEDDAL Study. Journal of Clinical Medicine, 14(19), 6705. https://doi.org/10.3390/jcm14196705
Vancouver
Núñez LM, Benito AR, Bereciartua E, Morata L, Escudero-Sánchez R, Nadal JS, et al. Real-World Use of Dalbavancin in Diabetic Foot Osteomyelitis: PEDDAL Study. Journal of Clinical Medicine. 2025;14(19):6705. doi:10.3390/jcm14196705
BibTeX
@article{Nez2025,
author = {Núñez, Leonor Moreno and Benito, Ana Rueda and Bereciartua, Elena and Morata, Laura and Escudero-Sánchez, Rosa and Nadal, Julia Sellares and Gómez-Junyent, Joan and Botrán, Alejandro Salinas and García, Ana María Arnáiz and Del Toro López, María Dolores and Ruiz-Cabrera, Diana and Andrino, José Miguel Ramos and Alidrous, Fatma and Torío-Salvador, Marina and Verdejo, Miguel Ángel and Velasco Arribas, María},
title = {Real-World Use of Dalbavancin in Diabetic Foot Osteomyelitis: PEDDAL Study},
journal = {Journal of Clinical Medicine},
year = {2025},
volume = {14},
number = {19},
pages = {6705},
doi = {10.3390/jcm14196705}
}
EUVIMED